id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-025920-9p5x26ge	Qadir, Nida	Adjunctive Therapies in ARDS: The Disconnect Between Clinical Trials and Clinical Practice	2020-06-03		.txt	text/plain	1215	67	43	In this issue of CHEST, Duggal et al 2 set out to address an important issue: the use of adjunctive therapies in patients with moderate to severe ARDS, a timely subject in the setting of COVID-19. Although the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG-SAFE) previously assessed the frequency of adjunctive therapy use all patients with ARDS, 3 a closer look at patients with a PaO 2 /FIO 2 ratio <150 is needed, as it is primarily this subset of patients in whom adjunctive therapies are recommended. This study 2 sheds some light on the patient-, clinician-, and systems-level factors associated with the use of adjunctive therapy, but many questions remain. Randomized controlled trials, including the Reevaluation Of Systemic Early Neuromuscular Blockade (ROSE) 6 and Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome (EOLIA), 7 chestjournal.org blockade or extracorporeal membrane oxygenation in patients with ARDS with specific levels of hypoxia. Patterns of use of adjunctive therapies in patients with early moderate to severe ARDS: insights from the LUNG SAFE Study	./cache/cord-025920-9p5x26ge.txt	./txt/cord-025920-9p5x26ge.txt